Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.
NPJ Vaccines
; 7(1): 118, 2022 Oct 12.
Article
em En
| MEDLINE
| ID: mdl-36224247
ABSTRACT
Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
NPJ Vaccines
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Canadá